Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

ClinicalTrials.gov ID: NCT03934814

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03934814. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Study identification

NCT ID: NCT03934814
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: I-Mab Biopharma US Limited; Industry
Enrollment: 98 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 16, 2019 (Actual)
Primary completion: Jan 10, 2023 (Actual)
Completion: Jan 10, 2023 (Actual)
Last update posted: Jul 1, 2024

2019 – 2023

United States locations

U.S. sites: 12
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of Alabama - Birmingham	Birmingham	Alabama	35233	—
Mayo Clinic	Scottsdale	Arizona	85259	—
Yale School of Medicine	New Haven	Connecticut	06510	—
Mayo Clinic	Jacksonville	Florida	32224	—
Horizon Oncology	Lafayette	Indiana	47905	—
University of Michigan	Ann Arbor	Michigan	48109	—
Henry Ford Cancer Institute/Henry Ford Hospital	Detroit	Michigan	48202	—
Mayo Clinic	Rochester	Minnesota	55905	—
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	—
NYU Langone Health	New York	New York	10016	—
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37203	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03934814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2024 · Synced Nov 14, 2026